🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Don’t miss this great opportunity! Rudnicki Lab @ottawahospital Research Institute is currently seeking innovative and creative #scientists to apply for faculty positions in the Regenerative Medicine Program. For more details and to apply visit: ohri.ca/Careers/Detail… #hiring

Are you looking for a Postdoctoral position? We have an NIH funded position just for you!! See: ohri.ca/Careers/Detail…

Are you looking for a Postdoctoral position? We have an NIH funded position just for you!! See: lnkd.in/eHja8rdd

Fantastic news from Satellos today!! lnkd.in/eE6--j8S

Today #RudnickiLab wishes farewell to Dr. Alex Lin (Alex Lin ), a postdoctoral fellow in our lab. Thank you for all your hard work, and congratulations on your well-deserved success. You can now find him working in an exciting position at Health Canada and PHAC!🎉

#RudnickiLab in Italy! 🇮🇹 This week, Dr. Bahareh Hekmatnejad (postdoctoral fellow) and John Saber (PhD candidate) have showcased interesting findings from our research at the #MyogenesisGordonResearchConference Gordon Research Conferences Gordon Myogenesis Conference 2023 (GRC/GRS)

David Glass is a renaissance man! A Scientist and a Playwrite!!

Congratulations to my son Isaac on his graduation!!! Very proud dad here. lnkd.in/eHNwDxYd

My son Jonathan graduated from Carleton University with his Masters in Journalism. Congratulations Jonathan!! Very proud. lnkd.in/ektY6-pj

The Regenerative Medicine Program at the Ottawa Hospital Research Institute has multiple Faculty Positions open for recruitment!!!!! lnkd.in/g_78UmAi

Great news and important milestone to bring our lead drug candidate for Duchenne into clinical trials!

Another important milestone for SAT-3247, our lead drug candidate in #Duchenne #musculardystrophy! #raredisease #rarediseases #PRV

Happy to share more from the large animal study of SAT-3247, our lead drug candidate in #Duchenne #musculardystrophy. These are important data in confirming the improved muscle regeneration and muscle function that we’ve seen in the mdx mouse models after treatment with SAT-3247.

Today, we are excited to announce the acceptance of our regulatory filing that allows us to begin our Phase 1 clinical trial with SAT-3247. We look forward to beginning enrollment in the study and dosing our first participant. Read the release for more details:

Our CEO Frank Gleeson spoke with Clinical Trials Arena about the details of our upcoming #clinicaltrials for SAT-3247, which we are developing as a novel #smallmolecule medicine for #Duchenne #musculardystrophy. Read the article here: clinicaltrialsarena.com/news/satellos-… #raredisease #rarediseases

This interview showcases not only the science behind Satellos Bioscience, but also the determination Frank Gleeson and I share to provide new hope for those who live valiantly with Duchenne muscular dystrophy and other degenerative muscle diseases. Well worth the listen!

Satellos Co-founder and CEO Frank Gleeson will be speaking at the @DefeatDuchenne Family Forum, a national education program specifically designed for families living with Duchenne muscular dystrophy. Frank will discuss the company’s lead drug candidate that is designed to

It's incredibly rewarding to see years of research progress to this milestone. The first participant has been dosed in the Phase 1 clinical study of SAT-3247! This brings us one step closer to changing how #Duchenne #musculardystrophy is treated. #ScienceInAction

Exciting data from the SAT-3247 study in a canine model of Duchenne!

When you're designing a drug for a patient population that is severely compromised or facing additional challenges, efficacy isn't the only consideration. The end goal is an easy to administer medication with a benign side effect profile that could fit well into a full regimen of